New research in the October 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the rate of bone mineral density (BMD) testing in people with prostate cancer undergoing androgen deprivation therapy (ADT) has improved in recent years, but remains low.
Ongoing updates are underway for NCCN Guidelines for Breast Cancer in Chinese, English, French, Japanese, Korean, Spanish, Polish, and Portuguese, free online at NCCN.org/global. Follow #NCCNGlobal for more. The NCCN Foundation is hosting free metastatic breast cancer webinars for patients and caregivers on October 8 and 12 at NCCN.org/patients.
The National Comprehensive Cancer Network announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma, one of the most curable forms of pediatric cancer. They synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment.
NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy.
NCCN Virtual Policy Summit features congressional staffers and representatives from CMS, COA, BIO, and others, discussing legislative and regulatory approaches for reducing health care costs.
New international research in the September 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient. Multi-organ irAEs are more likely to happen sequentially rather than simultaneously.
NCCN Guidelines, containing expert recommendations for cancer care, are available in French, German, Italian, Portuguese, Russian, and Spanish can all be accessed for free at NCCN.org/global or via the free Virtual Library of NCCN Guidelines® App
NCCN announces new and updated Chinese language versions of NCCN Guidelines for AML, Breast Cancer, CLL/SLL, Colon Cancer, Gastric Cancer, Hairy Cell Leukemia, Head and Neck Cancers, Hodgkin Lymphoma, Melanoma (Cutaneous), Multiple Myeloma, Non-small Cell Lung Cancer, Primary Cutaneous Lymphomas, and T-Cell Lymphomas.
The NCCN Oncology Research Program announced plans to develop a program to scientifically evaluate and facilitate clinical trials on the efficacy of decitabine and cedazuridine with research funding provided by Taiho Oncology.
The NCCN Virtual Nursing Forum and Annual Congress: Hematologic Malignancies (#NCCNhem20) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online October 8-10.
The NCCN Oncology Research Program (ORP) today announced four projects selected to receive funding for clinical and pre-clinical evaluation of futibatinib (TAS-120) in collaboration with Taiho Oncology.
National Comprehensive Cancer Network issues Request for Proposals (RFP) for projects that develop and validate enduring approaches to improve the safe, effective, and efficient adoption of biosimilars in oncology.
The NCCN Distress Thermometer enables discussion and treatment of distress as part of routine care for people with cancer. This free resource is now translated into 46 languages for global accessibility.
New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or “liquid biopsies.” The researchers found coverage rate rose from 0% to 38% in three years. The policies also increased in scope from 2017-2019, going from one cancer type to 12.
The National Comprehensive Cancer Network (NCCN) has published a new NCCN Guidelines for Patients: Immunotherapy Side Effects focused on chimeric antigen receptor (CAR) T-cell therapy. This is book two in a series that includes another book on irAEs focused on immune checkpoint inhibitors.
New NCCN Guidelines for Patients: Immunotherapy Side Effects - Immune Checkpoint Inhibitors from National Comprehensive Cancer Network and NCCN Foundation shares information for patients and caregivers on how to recognize and manage adverse events from immune checkpoint inhibitors.
NCCN Guidelines for Pediatric Acute Lymphoblastic Leukemia (ALL) in Chinese, Japanese, French, Spanish, and Portuguese are now available for free at NCCN.org
Online summit from NCCN on 21st Century Cures Act includes bipartisan sponsors, regulatory authorities; examines the impact on and from COVID-19 on cancer care and technology; presents policy recommendations for using data to advance patient access to high-quality cancer care
New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission.
Newly-completed series of patient guidelines from National Comprehensive Cancer Network (NCCN) shares expert advice with patients and caregivers on treatment and prevention for most common head and neck cancers, including some that are HPV-related.
NCCN and the NCCN Foundation announce five new recipients for the 10th annual NCCN Foundation Young Investigator Awards (YIA) Program, overseen by the NCCN Oncology Research Program (ORP)
The NCCN 2020 Annual Conference (#NCCN2020) providing the latest updates on cancer treatment recommendations was initially postponed due to COVID-19. The CE-accredited sessions are now available as online webinars.
A recently-published, independent, peer-reviewed, international study in Current Urology measured reliability and transparency of online medical information for people with prostate cancer and their caregivers, and found the NCCN Guidelines for Patients® to be one of the most trustworthy resources.
NCCN Best Practices Committee publishes peer-reviewed feature in JNCCN presenting latest insights on how to keep oncology patients and healthcare workers safe during COVID-19 pandemic. Visit NCCN.org/covid-19 for continually-updated resources for patients, providers, and care systems.
New information from NCCN, ASCO, ASH, CDC, FDA, and others seeks to provide clear guidance on how to optimally manage cancer-related pain without exacerbating the ongoing opioid crisis—published jointly in the Journal of the National Comprehensive Cancer Network and JCO Oncology Practice.
National Comprehensive Cancer Network (NCCN) announces addition of UCLA Jonsson Comprehensive Cancer Center and UT Southwestern Simmons Comprehensive Cancer Center to not-for-profit alliance of leading cancer centers responsible for creating and updating NCCN Guidelines among other oncology activity.
Experts from Seattle Cancer Care Alliance share lessons learned from early experiences treating people with cancer during COVID-19 outbreak via free online article in JNCCN—Journal of the National Comprehensive Cancer Network
New research from the American Cancer Society in the March 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that younger cancer survivors are more likely to experience significant financial strain for food, housing, and monthly bills after diagnosis.
The National Comprehensive Cancer Network (NCCN) has published a curated list of high-impact measures for assessing quality improvements in cancer care. The recommendations reflect a landscape analysis from leading oncology experts in order to move the needle on cancer care standards in America.
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) announces four projects selected to receive support directed towards improving the quality of care for advanced ovarian cancer patients, funded through a collaboration with AstraZeneca.
National Comprehensive Cancer Network Postpones 2020 Annual Conference, Citing Precautions against Potential Patient Exposure to COVID-19
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) today announced three research projects selected to receive funding to improve healthcare provider performance and/or healthcare quality, focusing on enhancing patient care and outcomes for people with NSCLC.
Cancer care providers will gather in Orlando on March 20-22 for the National Comprehensive Cancer Network® (NCCN®) 2020 Annual Conference: Celebrating 25 Years of NCCN. The three-day, in-person conference features more than 30 educational sessions on state-of-the-art practices in cancer care.
Largest population-based analysis on factors that affect survival outcomes for HPV-positive oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) find significant racial and socioeconomic disparities, according to new study in JNCCN-Journal of the National Comprehensive Cancer Network.
February 4 is the 20th annual World Cancer Day. NCCN is commemorating its 25th anniversary year by looking back at the tremendous progress made against cancer over the past quarter-century and looking forward to further define and advance high-quality, high-value, patient-centered cancer care globally.
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) announces plans to evaluate futibatinib (TAS-120), an inhibitor of the fibroblast growth factor receptor (FGFR).
New research JNCCN—Journal of the National Comprehensive Cancer Network, using data from NHIS to examine self-reported drinking habits among people reporting a cancer diagnosis, finds 56.5% were current drinkers, 34.9% exceeded moderate drinking levels, and 21% engaged in binge drinking.
NCCN publishes new NCCN Guidelines for treating children, adolescents and young adults with pediatric aggressive mature B-cell lymphomas (common and curable forms of non-Hodgkin lymphoma), including Burkitt lymphoma and diffuse large B-cell lymphoma.
NCCN hosted an annual NCCN Patient Advocacy Summit: Delivering Value for Patients across the Oncology Ecosystem in Washington, DC, bringing together patients, advocates, clinicians, policy-makers, and others to share diverse perspectives on the meaning of value in cancer care.
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces proposals selected for funding, in collaboration with Pfizer Global Medical Grants, to improve the quality of care and outcomes for people with metastatic breast cancer (MBC).
NCCN Guidelines for Genetic/Familial Risk Assessment: Breast, Ovarian, and Pancreatic updated with new and expanded sections on risk assessment and management related to three major cancer types.
New research in the November 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network from Dana-Farber Cancer Institute examines the implications of invasive breast cancer after breast-conserving treatment for ductal carcinoma in situ (aka DCIS, a form of non-invasive breast cancer) and which factors could impact overall survival.
The National Comprehensive Cancer Network (NCCN) published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Cell Transplantation, (aka stem cell transplant or bone marrow transplant), with step-by-step information on best practices for this blood cancer treatment
The National Comprehensive Cancer Network (NCCN®) Oncology Research Program (ORP) announces plans to support a phase II randomized trial for lung cancer patients with EGFR mutation or who have never smoked.
Patients pay less out-of-pocket for metastatic breast cancer (MBC) treatment that aligns with recommendations from NCCN Guidelines, according to a new study from the O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham (UAB), published in the October 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network.
New research in the September 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that providers with more experience treating people with multiple myeloma have better outcomes than those with more limited experience.
The National Comprehensive Cancer Network® (NCCN®) hosted a policy summit at the National Press Club in Washington, DC, addressing how to define, measure, and apply quality in cancer care.
World-renowned experts on blood cancers are meeting in San Francisco on September 27-28, to learn about new, practice-changing strategies to manage patients with hematologic malignancies, at the NCCN 2019 Annual Congress: Hematologic Malignancies™ from National Comprehensive Cancer Network® (NCCN®)
A collaborative project from the National Comprehensive Cancer Network® (NCCN®), the African Cancer Coalition (ACC), the American Cancer Society (ACS), and others to improve cancer outcomes in Sub-Saharan Africa enters a new phase in Addis Ababa, Ethiopia, today.
The National Comprehensive Cancer Network® (NCCN®) has begun publishing updated versions of cancer care guidelines adapted for Spanish cancer care providers, in collaboration with the Excellence and Quality in Oncology (ECO) Foundation.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right